Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-302168S in Overweight/Obese Subjects
NCT06953063Phase 2Completed
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DA-302168S in obesity (5 arms), sponsored by Chengdu Diao Pharmaceutical Group. Primary endpoint: Percentage change in body weight at 16 weeks. Started May 2025; status: completed.
02
Drugs
DA-302168S
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06953063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953063.